Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0QUDXZ
ADC Name
A18-PE24
Synonyms
A18 PE24; A18PE24
   Click to Show/Hide
Drug Status
Investigative
Indication
In total 1 Indication(s)
Hepatocellular carcinoma [ICD11:2C12]
Investigative
Antibody Name
Anti-GPC3 mAb A18
  Antibody Info 
Antigen Name
Glypican-3 (GPC3)
  Antigen Info 
Payload Name
Pseudomonas exotoxin PE24
  Payload Info 
Therapeutic Target
Eukaryotic elongation factor 2 (EEF2)
  Target Info 
Linker Name
Undisclosed
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Inhibitory Concentration 5% (IC5) 
110
ng/mL
G1LG cells
Hepatocellular carcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Inhibitory Concentration 5% (IC5) 110.00 ng/mL Positive GPC3 expression (GPC3+++/++)
Method Description
Ten thousand cells were seeded in a 96-well cell culture plate (200 l per well), supplemented with purified immunotoxins at the indicated final concentrations, and incubated at 37°C for 3 days. Cell viability was determined by quantifying the enzymatic activity of the intracellular luciferase that was released by two rounds of freezing-thawing.

   Click to Show/Hide
In Vitro Model Hepatocellular carcinoma G1LG cells Homo sapiens
References
Ref 1 Highly Potent Immunotoxins Targeting the Membrane-distal N-lobe of GPC3 for Immunotherapy of Hepatocellular Carcinoma. J Cancer. 2022 Feb 14;13(4):1370-1384.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.